Health

Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6$9.7 Million, Up 3-4% Year-over-Year

Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31,…

1 week ago

Globus Medical Schedules First Quarter Earnings Release and Conference Call

AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its…

1 week ago

Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems

NETANYA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”) today highlighted the…

1 week ago

Vivos Therapeutics Reports Full Year 2025 Financial Results

April 15, 2026 16:20 ET  | Source: Vivos Therapeutics, Inc Full Year 2025 revenue increased 16% Integration of The Sleep…

1 week ago

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of…

1 week ago

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

April 15, 2026 16:05 ET  | Source: Adaptive Biotechnologies SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:…

1 week ago

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 Halle (Saale) / Munich,…

1 week ago

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

April 15, 2026 01:00 ET  | Source: BioVersys BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) -- Poster presentations to feature…

1 week ago

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for…

1 week ago

Nxera Pharmas QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia

Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ®…

2 weeks ago